Effektivnyy i bezopasnyy kontrol' glikemii s pomoshch'yu Diabetona MV: zalog uspeshnoy profilaktiki khronicheskikh oslozhneniy sakharnogo diabeta 2 tipa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prevention of micro- and macrovascular complications of type 2 diabetes mellitus is an important goal of modern medicine. The article discusses the issues of treatment of the disease, the pharmacological characteristics, efficacy, and safety of sulfonylurea medications; the main benefits of gliclazide are described. The results of international studies that have demonstrated that the use of gliclazide contributes not only to the long-term metabolic control, but also to prevention or delay of development of vascular complications, are presented.

Full Text

Restricted Access

About the authors

E. V Biryukova

Email: lena@obsudim.ru

T. B Danilova

References

  1. Fonseca VA. Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care 2009;32(suppl 2):151-56.
  2. Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998;14(15):439-45.
  3. Stumvoll M, Goldstein BJ, van Haeften TW. Pathogenesis of type 2 diabetes. Endocr Res 2007;32:19-37.
  4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
  5. Giorgino F, Laviola L, Leonardini A. Pathoysiolody of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005;68(1)22-9.
  6. Nyenwe EA, Jerkins TW, Umpierrez GE, Ki AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metab Clin and Experim 2011;60:1-23.
  7. Schmitz O, LundS, Andersen PH, etal. Optimizing insulin secretogogue therapy in patients with type 2 diabetes. Diabet Care 2002;25:342-46.
  8. Kimmel B, Inzucchi EM. Oral agents for type 2 diabetes: an Update. Clin Diabetes 2005;23(2):64-76.
  9. Tielmans A, Laloi-Michelin M, Coupaye M, et al. Drug treatment of type 2 diabetes. 2007;36(2):269-78.
  10. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17:11-5.
  11. Aguilar-Bryan L, Nichols CG, Wechsler SF. Cloning of the в-cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-26.
  12. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86(3):247-53.
  13. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.
  14. Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med. 1999;16:586-90.
  15. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  16. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 1999;42:845-48.
  17. Guillausseau PJ. Compliance and optimisation of oral antidiabetic therapy. A longitudinal study [in French]. Presse Med 2004;33:156-60.
  18. Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006;155(4):615-22.
  19. Cozma LS, Luzio SD, Dunseath GJ et al. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002;25:1271-76.
  20. Guillausseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab 2001;27:133-37.
  21. Hosker JP, Rudenski AS, Burnett MA et al. Similar reduction in first-and second-phase B-cell responsesat three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989;38:767-72.
  22. Van Haeften TW, Veneman TF, Gerich JE, van der Veen EA. Influence of gliclazide on glucose-stimulated insulin release in man. Metabolism 1991;40:751-55.
  23. Khaled AA, Sekaran M, Ikram SI. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomedical Research 2010;21(2): 147-55.
  24. Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N YAcad Sci 2010;1212(1):29-40.
  25. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care 2008;31(6):1260-66.
  26. Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna. Сердце 2004; 3:1: 5-8.
  27. Robertson RP, Harmon J, Tran POT, Poitout V. в-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(suppl1):119-24.
  28. Jennings P, Scott NA, Saniabadi AR, Belch JFF. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessement. Metabolism. 1992; 5:36-9.
  29. Sliwinska A, Rogalska A, Szwed M, et al. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep 2012;39(5):5253-67.
  30. Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000;49:17-20.
  31. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc. Drugs Ther 2004;18:113-19.
  32. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32(15):1900-908.
  33. Abdelmoneim AS, Eurich DT, Gamble JM et al. Risk of acute coronary events associated with glyburide compared to gliclazide use in patients with type 2 diabetes: A nested case-control Ssudy. Diabetes Obes Metab 2013:10.1111/ dom.12173.
  34. Moen MF, Zhan M, Hsu VH. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4(6):1121-27.
  35. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50:735-41.
  36. Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med 1999;16:586-90.
  37. Sifri SA, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial Int J Clin Pract 2011;65(11):1132-40.
  38. Aravind SR, Ismail SB, Balamurugan R. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Current Medical Research & Opinion 2012;28(8):1-8.
  39. Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND // Сахарный диабет 2011. № 3 С. 90-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies